X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Torrent Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs MYLAN (US) - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 TORRENT PHARMA   MYLAN
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
MYLAN
Dec-14
TORRENT PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,5504,238-   
Low Rs1,1442,986-   
Sales per share (Unadj.) Rs354.71,450.7-  
Earnings per share (Unadj.) Rs40.1174.8-  
Cash flow per share (Unadj.) Rs64.2281.3-  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.1721.1-  
Shares outstanding (eoy) m169.22378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.82.5 152.5%   
Avg P/E ratio x33.620.7 162.6%  
P/CF ratio (eoy) x21.012.8 163.3%  
Price / Book Value ratio x4.95.0 98.4%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8971,366,627 16.7%   
No. of employees `00014.725.0 58.8%   
Total wages/salary Rs m11,3530-   
Avg. sales/employee Rs Th4,083.021,955.7 18.6%   
Avg. wages/employee Rs Th772.30-   
Avg. net profit/employee Rs Th461.32,644.9 17.4%   
INCOME DATA
Net Sales Rs m60,021548,892 10.9%  
Other income Rs m2,988-3,200 -93.4%   
Total revenues Rs m63,009545,693 11.5%   
Gross profit Rs m13,493136,512 9.9%  
Depreciation Rs m4,08640,314 10.1%   
Interest Rs m3,08523,676 13.0%   
Profit before tax Rs m9,31069,323 13.4%   
Minority Interest Rs m0-284 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,5292,915 86.7%   
Profit after tax Rs m6,78166,123 10.3%  
Gross profit margin %22.524.9 90.4%  
Effective tax rate %27.24.2 645.9%   
Net profit margin %11.312.0 93.8%  
BALANCE SHEET DATA
Current assets Rs m52,623482,549 10.9%   
Current liabilities Rs m52,022377,257 13.8%   
Net working cap to sales %1.019.2 5.2%  
Current ratio x1.01.3 79.1%  
Inventory Days Days12078 153.2%  
Debtors Days Days76107 71.1%  
Net fixed assets Rs m85,016126,985 67.0%   
Share capital Rs m84619,410 4.4%   
"Free" reserves Rs m45,3760-   
Net worth Rs m46,222272,853 16.9%   
Long term debt Rs m41,115407,616 10.1%   
Total assets Rs m142,4321,099,028 13.0%  
Interest coverage x4.03.9 102.3%   
Debt to equity ratio x0.91.5 59.5%  
Sales to assets ratio x0.40.5 84.4%   
Return on assets %6.98.2 84.8%  
Return on equity %14.724.2 60.5%  
Return on capital %14.213.6 104.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,9800-   
CASH FLOW
From Operations Rs m8,94272,152 12.4%  
From Investments Rs m-47,070-56,901 82.7%  
From Financial Activity Rs m34,174-19,012 -179.7%  
Net Cashflow Rs m-3,655-3,761 97.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.1 Rs / USD

Compare TORRENT PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare TORRENT PHARMA With: TTK HEALTHCARE  PFIZER  JUBILANT LIFE SCIENCES  SHASUN PHARMA  WYETH LTD  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views On News

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 22, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - SANOFI INDIA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS